C S Spada

Summary

Affiliation: Allergan Inc
Country: USA

Publications

  1. ncbi Differential effects of alpha-adrenoceptor agonists on human retinal microvessel diameter
    C S Spada
    Department of Biological Sciences, Pharmaceutical Research and Development, Allergan, Inc, Irvine, California 92612 1599, USA
    J Ocul Pharmacol Ther 17:255-77. 2001
  2. ncbi Vascular activities of prostaglandins and selective prostanoid receptor agonists in human retinal microvessels
    Clayton S Spada
    Department of Biological Sciences, Pharmaceutical Research and Development, Allergan, Inc Irvine, CA 92612 1599, USA
    Exp Eye Res 75:155-63. 2002
  3. ncbi Platelet-activating factor causes goblet cell depletion in the conjunctiva
    D F Woodward
    Allergan, Inc, Discovery Research, Irvine, CA 92715
    Eur J Pharmacol 168:23-30. 1989
  4. ncbi Studies on leukotriene D4 as an eosinophil chemoattractant
    D F Woodward
    Department of Biological Sciences, Allergan Inc, Irvine, CA 92713 9534
    Drugs Exp Clin Res 17:543-8. 1991
  5. ncbi Time-dependent differences in the vasopermeability response to intradermal peptidoleukotrienes
    D F Woodward
    Allergan, Inc, Department of Biology, CA 92715
    J Lipid Mediat 1:63-73. 1989
  6. ncbi The pharmacology of bimatoprost (Lumigan)
    D F Woodward
    Allergan, Inc, Irvine, CA 92612, USA
    Surv Ophthalmol 45:S337-45. 2001
  7. ncbi Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro
    C S Spada
    Department of Biological Sciences, Allergan, Inc, Irvine, California
    J Leukoc Biol 55:183-91. 1994

Detail Information

Publications7

  1. ncbi Differential effects of alpha-adrenoceptor agonists on human retinal microvessel diameter
    C S Spada
    Department of Biological Sciences, Pharmaceutical Research and Development, Allergan, Inc, Irvine, California 92612 1599, USA
    J Ocul Pharmacol Ther 17:255-77. 2001
    ....
  2. ncbi Vascular activities of prostaglandins and selective prostanoid receptor agonists in human retinal microvessels
    Clayton S Spada
    Department of Biological Sciences, Pharmaceutical Research and Development, Allergan, Inc Irvine, CA 92612 1599, USA
    Exp Eye Res 75:155-63. 2002
    ..No significant changes in human retinal arteriolar diameters relative to baseline were observed in response to a broad panel of parent and derived compounds known to be selective for EP-, FP- and IP-prostanoid receptors...
  3. ncbi Platelet-activating factor causes goblet cell depletion in the conjunctiva
    D F Woodward
    Allergan, Inc, Discovery Research, Irvine, CA 92715
    Eur J Pharmacol 168:23-30. 1989
    ..The pronounced inhibitory activity of CV-6209 suggests that high doses of lyso-PAF may either weakly stimulate conjunctival PAF receptors or that there may be sufficient conversion of lyso-PAF to biologically active levels of PAF...
  4. ncbi Studies on leukotriene D4 as an eosinophil chemoattractant
    D F Woodward
    Department of Biological Sciences, Allergan Inc, Irvine, CA 92713 9534
    Drugs Exp Clin Res 17:543-8. 1991
    ..These studies indicate that LTD4 may cause eosinophil emigration in vivo according to tissue-dependent regulation...
  5. ncbi Time-dependent differences in the vasopermeability response to intradermal peptidoleukotrienes
    D F Woodward
    Allergan, Inc, Department of Biology, CA 92715
    J Lipid Mediat 1:63-73. 1989
    ..The time-dependent effects of LTD4 on albumin extravasation cannot be ascribed to leukocyte infiltration into the skin since LTC4, LTD4, and LTE4 were entirely without effect in this regard...
  6. ncbi The pharmacology of bimatoprost (Lumigan)
    D F Woodward
    Allergan, Inc, Irvine, CA 92612, USA
    Surv Ophthalmol 45:S337-45. 2001
    ..The sclera is the preferred route of accession to the eye. The high scleral permeability coefficient Papp is a likely contributing factor to the rapid onset and long-acting ocular hypotensive profile of bimatoprost...
  7. ncbi Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro
    C S Spada
    Department of Biological Sciences, Allergan, Inc, Irvine, California
    J Leukoc Biol 55:183-91. 1994
    ..These studies suggest that leukotriene D4 may behave as a potent and selective chemoattractant for human eosinophils at physiologically relevant concentrations...